Blocked Pathways: FTIs Shut Down Oncogene Signals

Blocked Pathways: FTIs Shut Down Oncogene Signals Saïd M. Sebti Oncologist 2003; 8(Suppl 3): 30-38 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe how mutations in ras oncogenes affect cell signal transduction pathways and disrupt cell growth, differentiation, proliferation, and survival. Identify the mechanisms of action of two classes of prenylation inhibitors, the farnesyl transferase inhibitors (FTIs) and the geranylgeranyl transferase-I inhibitors (GGTIs). Explain the in vitro and in vivo antitumor activity of FTIs and GGTIs in multiple myeloma and myelodysplastic syndrome. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Click Here to return to the complete course listing of Penetrating Insights: Crossing the Cancer Cell Membrane to Improve Clinical Outcomes.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 12, 2003 Most Recent Review: June 10, 2005* Most Recent Update: Dec. 12, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.